On the basis of these data, patients with EGFR- and ALK-mutated tumors were excluded from most randomized trials evaluating ICIs in combination with chemotherapy versus chemotherapy alone as frontline treatment for patients with advanced NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.